...
首页> 外文期刊>Drug safety: An international journal of medical toxicology and drug experience >Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation.
【24h】

Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation.

机译:在大型,可管理的护理组织中,与抗菌药物使用相关的过敏反应发生率。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Data on the incidence of serious allergic reactions to fluoroquinolone antibacterials are mainly derived from spontaneous reports that cannot be used to accurately estimate incidence. METHODS: This study estimated the drug-specific incidence of serious allergic reactions after fluoroquinolone, cephalosporin and phenoxymethylpenicillin potassium exposure, using claims for healthcare services with confirmation through medical record abstraction within a large health insurer database. Cohorts exposed to each antibacterial of interest (moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin, cephalosporins and penicillin) were identified, and followed for 14 days for anaphylaxis (9th revision of the International Classification of Diseases [ICD-9] code 995.0), other allergic drug reactions (ICD-9 995.2, 995.3) or cardiopulmonary resuscitation. RESULTS: The incidence per 10,000 first dispensings of any allergic diagnosis made in the hospital or emergency department was similar for moxifloxacin (4.3; 95% CI 3.5, 5.3), penicillin (4.7; 95% CI 3.8, 5.7) and ciprofloxacin (5.4; 95% CI 4.4, 6.5). The incidence for moxifloxacin was lower than that for levofloxacin (8.7; 95% CI 7.4, 10.0), gatifloxacin (6.7; 95% CI 5.6, 7.9) and the cephalosporins (7.5; 95% CI 6.3, 8.8). The incidence of anaphylaxis/anaphylactoid reactions after first dispensings was similar for the fluoroquinolones: 0.1 (95% CI 0.0, 0.3) for ciprofloxacin, 0.3 (95% CI 0.1, 0.5) for moxifloxacin, 0.3 (95% CI 0.1, 0.6) for gatifloxacin and 0.5 (95% CI 0.3, 0.9) for levofloxacin; and comparable with that of the cephalosporins (0.2; 95% CI 0.0, 0.4) and penicillin (0.1; 95% CI 0.0, 0.3). CONCLUSIONS: Anaphylactic reactions were rare and their incidence did not differ substantially among the drug groups studied. By determining the occurrence of reactions following defined exposures, these results provide a context for the interpretation of spontaneous reports of allergic reactions.
机译:背景:关于氟喹诺酮类抗生素严重过敏反应发生率的数据主要来自自发报告,不能用于准确估计发生率。方法:本研究使用大型医疗保险公司数据库中的医疗记录摘要,通过对医疗服务的索赔和确认来估计氟喹诺酮,头孢菌素和苯氧甲基青霉素钾暴露后严重过敏反应的药物特异性发生率。确定了暴露于每种感兴趣的抗菌药物(莫西沙星,左氧氟沙星,环丙沙星,加替沙星,头孢菌素和青霉素)的队列,随后进行了14天的过敏反应(国际疾病分类[ICD-9]第9版,代码995.0)和其他过敏性疾病。药物反应(ICD-9 995.2、995.3)或心肺复苏。结果:在医院或急诊科进行的任何过敏性诊断的每10,000次首次配发的发生率与莫西沙星(4.3; 95%CI 3.5,5.3),青霉素(4.7; 95%CI 3.8,5.7)和环丙沙星(5.4; 95%CI 4.4、6.5)。莫西沙星的发生率低于左氧氟沙星(8.7; 95%CI 7.4,10.0),加替沙星(6.7; 95%CI 5.6,7.9)和头孢菌素(7.5; 95%CI 6.3,8.8)。氟喹诺酮类药物的首次过敏反应/类过敏反应发生率相似:环丙沙星为0.1(95%CI 0.0,0.3),莫西沙星为0.3(95%CI 0.1,0.5),氟西沙星为0.3(95%CI 0.1,0.6)加替沙星和左氧氟沙星0.5(95%CI 0.3,0.9);与头孢菌素(0.2; 95%CI 0.0,0.4)和青霉素(0.1; 95%CI 0.0,0.3)相当。结论:过敏反应很少见,在所研究的药物组中其发生率没有实质性差异。通过确定特定暴露后反应的发生,这些结果为解释过敏反应的自发报告提供了背景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号